Working to Save Lives Collectively Theme Highlights Two Many years of Profitable Collaboration with the Worldwide Medical and Analysis Communities to Assist Sufferers Survive Life-Threatening Sicknesses
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) — CytoSorbents Company (NASDAQ: CTSO), a frontrunner within the remedy of lethal situations within the intensive care unit and cardiac surgical procedure utilizing blood purification by way of its proprietary polymer adsorption expertise, is proud to announce the launch of its newly redesigned and consolidated web site at www.cytosorbents.com. The theme of Working to Save Lives Collectively highlights 20 years of profitable collaboration with the worldwide medical and analysis communities to constantly refine how our therapies, resembling CytoSorb ®, ECOS-300CY ®, and VetResQ ® are getting used to assist sufferers survive life-threatening sicknesses.
A Trendy, Unified On-line Presence
The brand new web site, constructed from the bottom up, unifies our company and product info right into a single, cohesive and complete info hub for healthcare professionals, traders, and different key stakeholders. Guests will discover a streamlined trendy design, intuitive navigation, and in depth content material on our firm, expertise, therapies, pipeline that features DrugSorb™-ATR and HemoDefend-BGA™, scientific research, investor conferences, and rather more.
Key Options of the New Web site:
- Consumer-Pleasant Format and Intuitive Navigation – with easy accessibility to important info and optimized for each desktop and cell looking.
- Enhanced Simple-to-Perceive Content material – tailor-made for various stakeholders.
- Information and Updates – devoted to the newest developments and occasions.
- Complete and Searchable Useful resource Library – from a set of 1,000+ peer-reviewed publications, poster shows, abstracts, white papers and case studies highlighting using our therapies in lots of functions.
- Introduction to Our Consultants – who’re there to supply steering and assist.
- Voices Across the World – with insights and suggestions from customers worldwide.
- Devoted Investor Relations website – for fast entry to investor supplies.
- Improved Contact Kinds – facilitating quicker communications and interactions.
Dr. Christian Steiner, Government Vice President of Gross sales and Advertising of CytoSorbents, said, We’re grateful to the entire pioneering physicians, nurses, perfusionists, researchers, and different healthcare professionals who use our therapies in day by day scientific follow or who’ve contributed to the various research and the greater than 1,000 references that may be present in our CytoSorb literature database on our new web site. Your dedication and insights have been instrumental in shaping the success of our expertise and enhancing affected person outcomes worldwide. Likewise, as we’ve prior to now, it’s our dedication to you to be a trusted and reliable accomplice who might be there to assist you everytime you want us.
Dr. Steiner added, We invite everybody to discover the brand new CytoSorbents web site which is a celebration of all that we’ve completed collectively, and to find out how CytoSorbents helps to avoid wasting lives and ˜Broaden the Dimension of Blood Purification™’ with our merchandise around the globe.
About CytoSorbents Company (NASDAQ: CTSO)
CytoSorbents Company is a frontrunner within the remedy of life-threatening situations within the intensive care unit and in cardiac surgical procedure by way of blood purification. Its lead product, CytoSorb ®, is authorized within the European Union and distributed in 75 international locations worldwide. It’s an extracorporeal cytokine adsorber that reduces cytokine storm or cytokine launch syndrome in frequent important sicknesses that may result in huge irritation, organ failure and affected person loss of life. In these ailments, the danger of loss of life might be extraordinarily excessive, and there are few, if any, efficient remedies. CytoSorb can be used throughout and after cardiothoracic surgical procedure to take away antithrombotic medication and inflammatory mediators that may result in postoperative problems, together with extreme bleeding and a number of organ failure. As of March 31, 2024, greater than 237,000 CytoSorb gadgets have been used cumulatively. CytoSorb was initially launched within the European Union below CE mark as the primary cytokine adsorber. Extra CE mark extensions had been granted for bilirubin and myoglobin removing in scientific situations resembling liver illness and trauma, respectively, and for ticagrelor and rivaroxaban removing in cardiothoracic surgical procedure procedures. CytoSorb has additionally obtained FDA Emergency Use Authorization in america to be used in grownup critically sick COVID-19 sufferers with impending or confirmed respiratory failure. CytoSorb just isn’t but authorized in america.
The DrugSorb™-ATR antithrombotic removing system, an investigational machine based mostly on the identical polymer expertise as CytoSorb, has obtained two FDA Breakthrough System Designations, one for the removing of ticagrelor and one other for the removing of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit throughout pressing cardiothoracic procedures. The Firm has accomplished the FDA-approved, randomized, managed STAR-T (Secure and Well timed Antithrombotic Elimination-Ticagrelor) examine of 140 sufferers at roughly 30 facilities in U.S. and Canada to guage whether or not intraoperative use of DrugSorb-ATR can scale back the perioperative danger of bleeding in sufferers receiving ticagrelor and present process cardiothoracic surgical procedure. This pivotal examine is meant to assist U.S. FDA and Well being Canada advertising approval for DrugSorb-ATR on this utility.
CytoSorbents’ purification applied sciences are based mostly on biocompatible, extremely porous polymer beads that may actively take away poisonous substances from blood and different bodily fluids by pore seize and floor adsorption. Its applied sciences have obtained non-dilutive grant, contract, and different funding of roughly $50 million from DARPA, the U.S. Division of Well being and Human Providers (HHS), the Nationwide Institutes of Well being (NIH), Nationwide Coronary heart, Lung, and Blood Institute (NHLBI), the U.S. Military, the U.S. Air Power, U.S. Particular Operations Command (SOCOM), Air Power Materials Command (USAF/AFMC), and others. The Firm has quite a few marketed merchandise and merchandise below improvement based mostly upon this distinctive blood purification expertise protected by many issued U.S. and worldwide patents and registered emblems, and a number of patent functions pending, together with ECOS-300CY ®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ ®, Ok+ontrol™, DrugSorb™, ContrastSorb, and others. For extra info, please go to the Firm’s web sites at www.cytosorbents.com and www.cytosorb.com or observe us on Fb (NASDAQ:) and X.
Ahead-Wanting Statements
This press launch consists of forward-looking statements supposed to qualify for the secure harbor from legal responsibility established by the Personal Securities Litigation Reform Act of 1995. These forward-looking statements embrace, however aren’t restricted to, statements about our plans, goals, future targets and outlooks for our enterprise, statements about potential exposures ensuing from our money positions, representations and contentions, and aren’t historic details and sometimes are recognized by use of phrases resembling might, ought to, might, count on, plan, anticipate, imagine, estimate, predict, potential, proceed and comparable phrases, though some forward-looking statements are expressed in a different way. You have to be conscious that the forward-looking statements on this press launch signify administration’s present judgment and expectations, however our precise outcomes, occasions and efficiency might differ materially from these within the forward-looking statements. Components which might trigger or contribute to such variations embrace, however aren’t restricted to, the dangers mentioned in our Annual Report on Type 10-Ok, filed with the SEC on March 14, 2024, as up to date by the dangers reported in our Quarterly Studies on Type 10-Q, and within the press releases and different communications to shareholders issued by us every now and then which try to advise events of the dangers and components which can have an effect on our enterprise. We warning you to not place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly replace or revise any forward-looking statements, whether or not because of new info, future occasions, or in any other case, apart from as required below the Federal securities legal guidelines.
Please Click on to Comply with Us on Fb and X
U.S. Firm Contact:
Kathleen Bloch, CFO
305 Faculty Street East
Princeton, NJ 08540
+1 (732) 398-5429
[email protected]
Investor Relations Contact:
Eric Ribner
LifeSci Advisors, LLC
250 W 55th St, #3401
New York, NY 10019
+1 (646) 751-4363
[email protected]